CD4 and cancer: In chronic myeloid leukaemia (CML) cancer models, dasatinib may increase the number of Granzyme B (GrB) expressing memory CD4+ T cells (GrB+CD4+ T‐cells) and promote their differentiation into Th1‐type T‐cells, which in turn produce interferon‐gamma, a powerful tumour‐suppressive cytokine 161.